Lonza Group AG Share Price

Equities

LONN

CH0013841017

Biotechnology & Medical Research

Real-time Estimate Cboe Europe 04:32:06 13/06/2024 pm IST 5-day change 1st Jan Change
483.8 CHF -0.28% Intraday chart for Lonza Group AG -4.48% +36.75%

Financials

Sales 2024 * 665.69Cr 743.09Cr 62TCr Sales 2025 * 762.51Cr 851.17Cr 71TCr Capitalization 3.5TCr 3.91TCr 3,26200Cr
Net income 2024 * 89Cr 100Cr 8.33TCr Net income 2025 * 110.7Cr 123.57Cr 10TCr EV / Sales 2024 * 5.66 x
Net Debt 2024 * 271.56Cr 303.13Cr 25TCr Net Debt 2025 * 331.91Cr 370.5Cr 31TCr EV / Sales 2025 * 5.02 x
P/E ratio 2024 *
39.2 x
P/E ratio 2025 *
31.3 x
Employees 18,000
Yield 2024 *
0.93%
Yield 2025 *
1.09%
Free-Float 96.79%
More Fundamentals * Assessed data
Dynamic Chart
1 day-0.28%
1 week-4.44%
Current month-0.51%
1 month-6.29%
3 months+2.70%
6 months+48.44%
Current year+36.81%
More quotes
1 week
473.70
Extreme 473.7
511.80
1 month
473.70
Extreme 473.7
533.40
Current year
339.00
Extreme 339
559.40
1 year
308.60
Extreme 308.6
574.60
3 years
308.60
Extreme 308.6
785.40
5 years
301.00
Extreme 301
785.40
10 years
90.90
Extreme 90.9
785.40
More quotes
Managers TitleAgeSince
Chief Executive Officer 72 25/17/25
Director of Finance/CFO 52 01/21/01
Chief Operating Officer 55 01/22/01
Members of the board TitleAgeSince
Director/Board Member 63 16/14/16
Director/Board Member 66 16/14/16
Director/Board Member 58 05/22/05
More insiders
Date Price Change Volume
13/24/13 483.8 -0.27% 49 171
12/24/12 485.1 -2.02% 341,121
11/24/11 495.1 -1.18% 156,282
10/24/10 501 +0.16% 118,736
07/24/07 500.2 -1.22% 130,013

Delayed Quote Swiss Exchange, June 13, 2024 at 04:01 pm IST

More quotes
Lonza Group AG is one of the world leaders of the development, production and marketing of chemical products. Net sales break down by family of products and services as follows: - bio-pharmaceuticals (52.6%): exclusive syntheses, microbiological fermentation products , mammalian cell cultures, etc.; - capsules and dosing solutions for biopharmaceuticals, drugs and nutrition products (20.3%). In addition, the group offers nutritional ingredients; - small molecule drug substances (13.2%); - technologies and platforms for manufacturing processes and production of cell and gene therapies (11.1%); - other (2.8%). Net sales are distributed geographically as follows: Switzerland (16%), Europe (29.8%), the United States (38.8%), the Americas (3%), Japan (3.7%), China (2.6%), Asia (5.8%) and other (0.3%).
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
A
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
485.1 CHF
Average target price
582.3 CHF
Spread / Average Target
+20.04%
Consensus